Imbruvica

Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases.